Isotopia Molecular Imaging

Company Overview

Snapshot

Founded in February 2007 by Eli Shalom, Isotopia Molecular Imaging operates with 51–200 employees. The company has secured $3.75 million across one funding round from one investor. In March 2025, Isotopia officially launched Isoprotrace® in Germany, expanding access to advanced prostate cancer imaging.

Business overview

Isotopia Molecular Imaging is a global pharmaceutical company specializing in the development, production, and distribution of diagnostic and therapeutic radioactive isotopes, including advanced PET and SPECT radiotracers. Its core technology focuses on radioisotopes like Lutetium-177, which shows promise in treating late-stage cancers such as metastatic prostate cancer and neuroendocrine tumors. The company serves the health tech and life sciences sectors, providing solutions for cancer therapy, diagnostics, and research to hospitals, pharma companies, and healthcare providers.

Strategic signal

Isotopia Molecular Imaging is actively expanding its market reach for advanced radiopharmaceuticals. In May 2025, the company partnered with Cardirad to launch Isoprotrace® in Sweden and Denmark, following its official commercial launch in Germany in March 2025 with DSD Pharma. This strategic expansion into key European markets signals a strong focus on commercialization and broader patient access to its prostate cancer imaging solutions, indicating a positive growth trajectory for investors.

Company Intelligence Q&A

What was the most recent product launch for Isotopia Molecular Imaging?

In May 2025, Isotopia Molecular Imaging, in partnership with Cardirad, launched Isoprotrace® in Sweden and Denmark. This advanced Gallium-68 Gozetotide aims to expand access to advanced prostate cancer imaging.

What strategic supply agreement did Isotopia Molecular Imaging announce?

In January 2025, Isotopia Molecular Imaging and Kinectrics announced an agreement for the supply of Gadolinium-160 (Gd-160). This supply is intended to support the production of Terbium-161 (Tb-161) for advanced radiotherapeutics.

When did Isotopia Molecular Imaging launch Isoprotrace in Germany?

In March 2025, Isotopia Molecular Imaging officially launched Isoprotrace® in Germany, partnering with DSD Pharma to introduce the innovative radio-pharmaceutical.

What collaboration did Isotopia Molecular Imaging establish regarding Lutetium-177?

In September 2022, Clovis Oncology and Isotopia Molecular Imaging announced a Lutetium-177 Clinical Supply Agreement.

What production agreement did Isotopia Molecular Imaging make for n.c.a. Lu-177?

In September 2020, Isotopia Molecular Imaging and CPDC announced a production agreement for n.c.a. Lu-177.